---
title: "JOINN Laboratories Flags Surging Interim Profit on Biological Asset Gains"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292628989.md"
description: "JOINN Laboratories (HK:6127) forecasts H1 2026 net profit of RMB600.1-900.2 million, up significantly from RMB60.9 million last year, driven by fair value gains in biological assets rather than core operations. Revenue is expected to rise 10.5% YoY to RMB668.6-739.0 million. Despite the profit surge, analyst ratings remain 'Hold' with a HK$16.30 target."
datetime: "2026-07-14T12:38:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292628989.md)
  - [en](https://longbridge.com/en/news/292628989.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292628989.md)
generator: "portal-rs"
---

# JOINN Laboratories Flags Surging Interim Profit on Biological Asset Gains

JOINN Laboratories (China) Co., Ltd. Class H ( (HK:6127) ) has issued an announcement.

JOINN Laboratories (China) Co., Ltd. has issued an earnings estimate for the first half of 2026, forecasting revenue between RMB668.6 million and RMB739.0 million, up as much as 10.5% year on year. The company expects a sharp jump in net profit attributable to shareholders to between RMB600.1 million and RMB900.2 million, compared with RMB60.9 million a year earlier.

The projected net profit after excluding non-recurring items is seen rising to RMB561.1 million to RMB841.7 million, driven largely by substantial gains from changes in the fair value of biological assets. In contrast, the core laboratory services and other businesses are expected to deliver a net result ranging from a loss of RMB141.6 million to a profit of RMB65.0 million, highlighting that profit growth is heavily reliant on biological asset valuation gains rather than operating improvement.

The most recent analyst rating on (HK:6127) stock is a Hold  
 with a HK$16.30 price target.  
 To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock,  
 see the HK:6127 Stock Forecast page. 

**More about JOINN Laboratories (China) Co., Ltd. Class H**

JOINN Laboratories (China) Co., Ltd. is a China-incorporated joint stock company listed in Hong Kong, operating in the contract research and laboratory services sector. The group provides laboratory-based services and related businesses, and also records gains and losses from biological assets, which form a significant component of its financial performance.

**Average Trading Volume:** 4,033,256

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$33.89B

Find detailed analytics on 6127 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [06127.HK](https://longbridge.com/en/quote/06127.HK.md)
- [603127.CN](https://longbridge.com/en/quote/603127.CN.md)

## Related News & Research

- [Joinn Laboratories signs RMB 10.71 million right-of-use asset lease with Beijing Joinn Biologics](https://longbridge.com/en/news/297477624.md)
- [JOINN  Surges Over 7%; Interim Profit Expected to Jump Up to 13.77x to RMB900 Million](https://longbridge.com/en/news/292695646.md)
- [Ju Fu Tang Biotech holds annual shareholder meeting](https://longbridge.com/en/news/298578782.md)
- [LongBio Pharma names Xue Kailu non-executive director after EGM vote](https://longbridge.com/en/news/298597482.md)
- [08:00 ETMinistry of Food and Drug Safety of Korea, Successfully Concludes 'GBC 2026,' Marking a Great Leap in Bio](https://longbridge.com/en/news/298210868.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**